Amalgamated Bank Buys 427 Shares of Jazz Pharmaceuticals PLC $JAZZ

Amalgamated Bank increased its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 1.5% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 28,013 shares of the specialty pharmaceutical company’s stock after purchasing an additional 427 shares during the quarter. Amalgamated Bank’s holdings in Jazz Pharmaceuticals were worth $2,973,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. Retirement Systems of Alabama increased its position in shares of Jazz Pharmaceuticals by 0.9% during the 2nd quarter. Retirement Systems of Alabama now owns 190,390 shares of the specialty pharmaceutical company’s stock valued at $20,204,000 after purchasing an additional 1,750 shares during the last quarter. Assetmark Inc. grew its position in Jazz Pharmaceuticals by 9,759.8% in the 2nd quarter. Assetmark Inc. now owns 83,118 shares of the specialty pharmaceutical company’s stock valued at $8,820,000 after acquiring an additional 82,275 shares during the last quarter. Hantz Financial Services Inc. grew its position in Jazz Pharmaceuticals by 471.4% in the 2nd quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock valued at $38,000 after acquiring an additional 297 shares during the last quarter. Arkadios Wealth Advisors grew its position in Jazz Pharmaceuticals by 8.8% in the 2nd quarter. Arkadios Wealth Advisors now owns 13,825 shares of the specialty pharmaceutical company’s stock valued at $1,467,000 after acquiring an additional 1,115 shares during the last quarter. Finally, Teacher Retirement System of Texas grew its position in Jazz Pharmaceuticals by 0.6% in the 2nd quarter. Teacher Retirement System of Texas now owns 15,560 shares of the specialty pharmaceutical company’s stock valued at $1,651,000 after acquiring an additional 90 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock opened at $138.38 on Tuesday. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $148.06. The stock has a market capitalization of $8.39 billion, a price-to-earnings ratio of -20.56, a P/E/G ratio of 8.49 and a beta of 0.28. The stock has a fifty day simple moving average of $132.47 and a two-hundred day simple moving average of $118.61. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The firm had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.05 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.Jazz Pharmaceuticals’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $5.30 earnings per share. On average, analysts predict that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have commented on JAZZ shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, August 28th. Wells Fargo & Company set a $170.00 price objective on Jazz Pharmaceuticals in a research report on Wednesday, October 22nd. Zacks Research raised Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Friday, August 15th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Jazz Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft started coverage on Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They issued a “buy” rating and a $152.00 price objective on the stock. Fourteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $179.33.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, Director Bruce C. Cozadd sold 3,500 shares of the company’s stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $140.00, for a total transaction of $490,000.00. Following the completion of the sale, the director directly owned 408,826 shares in the company, valued at $57,235,640. This represents a 0.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. In the last three months, insiders sold 11,500 shares of company stock worth $1,525,280. Corporate insiders own 4.30% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.